Journal Article Summary
The article investigates the effectiveness of levetiracetam, a medication used to treat epilepsy, by examining how many patients continued using it after one year. Understanding the long-term use of this medication is important because it helps to assess its real-life effectiveness and informs healthcare providers about patient experiences. This study is particularly relevant for patients and caregivers who are considering or currently using levetiracetam, as it provides insights into its continuation rates and factors influencing treatment decisions.
The researchers followed 794 adults with epilepsy who started taking levetiracetam between January and August of 2005 or 2006. After one year, they found that 83.5% of the patients continued their treatment. Among those who remained on the medication, nearly half were seizure-free in the last six months of the study, and a significant portion was using levetiracetam alone. The main reasons for stopping the medication included side effects and insufficient effectiveness, with previous treatment history playing a role in discontinuation.
While the study provides valuable information, it has limitations, such as its focus on a specific patient population in France, which may not reflect experiences in other regions. Patients should be aware that individual responses to levetiracetam can vary, and factors like prior treatments can influence outcomes. It is essential for patients and caregivers to discuss any concerns or experiences with their healthcare professionals to ensure the best treatment plan is in place.
Medical Safety Note
This journal article summary is provided for educational purposes only and is not medical advice. Always consult a licensed healthcare professional before starting, stopping, or changing any medication.
Article Cited
- Droz-Perroteau Cécile, Dureau-Pournin Caroline, Vespignani Hervé, Marchal Cécile, Blin Patrick, Blazejewski Sylvie, Pollet Clothilde, Jové Jérémy, et al.. The EULEV cohort study: rates of and factors associated with continuation of levetiracetam after 1 year. British Journal of Clinical Pharmacology 2011. DOI: 10.1111/j.1365-2125.2010.03805.x. PMID: 21143508. PMCID: PMC3018033.
Featured Pill Pals Product
Levetiracetam 500 mg Tablets --- Generic For Keppra --- Rising Pharma
Levetiracetam 500 mg Tablets — Generic For Keppra — Rising Pharma is available through Pill Pals Pharmacy with cash-pay pharmacy pricing and free shipping where available. Prescription required.
Request a prescription transfer and our pharmacy team will help coordinate the next step.
